FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma

 The FDA has instituted a clinical hold on Legend Biotech Corporation's 

LEGN +2.22%

 (Get Free Alerts for LEGN) Phase 1 trial for LB1901. 

• LB1901 is the company's investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). 
• The FDA indicated they would provide an official clinical hold letter to Legend Biotech by March 11.
• To date, one patient has been dosed in the clinical trial. 
• Before receiving the FDA's clinical hold communication, Legend Biotech had, under the protocol, paused the clinical trial due to low CD4+ T-cell counts in the patient's peripheral blood and notified the FDA. 
• The patient has not experienced drug-related serious adverse events (SAEs) and is being monitored.

https://www.benzinga.com/general/biotech/22/02/25635068/fda-slams-brakes-on-legend-biotechs-car-t-therapy-trial-in-lymphoma-patients